Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 5/20 | 0.86 |
| ▸ | TUBB | P07437 | 5/20 | 0.86 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.86 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.86 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.86 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.86 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.86 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.86 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.86 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.86 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.86 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.86 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.86 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.86 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.86 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.82 |
| ▸ | XDH | P47989 | 3/20 | 0.82 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | PKM | P14618 | 1/20 | 0.74 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13560795 | 1.00 | TUBB4A (0.86) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Chrysosplenol B SCHEMBL29558792 | 0.93 | ABCG2 (0.78) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL31589078 | 0.93 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29647956 | 0.93 | TUBB4A (0.74) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Chrysosplenol B SCHEMBL2369883 | 0.93 | ABCG2 (0.78) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL31589366 | 0.93 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL19461012 | 0.93 | TUBB4A (0.74) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Chrysosplenol C SCHEMBL4742072 | 0.90 | ABCG2 (0.73) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Centaureidin SCHEMBL9953 | 0.90 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Axillarin SCHEMBL29929599 | 0.90 | XDH (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230119060-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE | MEDIENCE CO., LTD. (KR) | 2023-04-20 | — | — | US | claimed |
| EP-4580594-A1 | ANTIOXIDANT COMPOSITION COMPRISING 5-DEOXYFLAVONOIDS | AnalytiCon Discovery - Zweigniederlassung der BRAIN Biotech AG (DE) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024046834-A1 | ANTIOXIDANT COMPOSITION COMPRISING 5-DEOXYFLAVONOIDS | ANALYTICON DISCOVERY GMBH (DE) | 2024-03-07 | — | — | WO | disclosed |
| EP-4331564-A1 | ANTIOXIDANT COMPOSITION COMPRISING 5-DEOXYFLAVONOIDS | Analyticon Discovery GmbH (DE) | 2024-03-06 | — | — | EP | disclosed |
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-18 | — | — | US | disclosed |
| CN-116942833-A | Human bacteria inducing proliferation or accumulation of regulatory T cells | 国立大学法人 东京大学 | 2023-10-27 | — | — | CN | disclosed |
| CN-116836953-A | Mugwort oxymethyl transferase FOMT4, and encoding gene, vector and application thereof | 湖北中医药大学 | 2023-10-03 | — | — | CN | disclosed |
| EP-4243809-A2 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | Beth Israel Deaconess Medical Center, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230255989-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-08-17 | — | — | US | disclosed |
| CN-108676774-B | Human bacteria inducing proliferation or accumulation of regulatory T cells | 国立大学法人东京大学 | 2023-05-09 | — | — | CN | disclosed |
| US-20230119060-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE | MEDIENCE CO., LTD. (KR) | 2023-04-20 | — | — | US | disclosed |
| EP-3013331-B1 | MULTITARGET HEDGEHOG PATHWAY INHIBITORS AND THEIR USE FOR THE TREATMENT OF CERTAIN HEDGEHOG (HH)-DEPENDENT TUMORS | UNIV DEGLI STUDI DI SIENA (IT) | 2023-03-01 | — | — | EP | disclosed |
| WO-2022104153-A2 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| US-11304927-B2 | Bioactive extract, fraction of Cassia occidentalis and formulation thereof for bone regeneration | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11304927-B2 | Bioactive extract, fraction of Cassia occidentalis and formulation thereof for bone regeneration | BMP4, BMP2, BMP1 | TUBB4A 3879/4885TUBB 4249/4885TUBA3C 4863/4885 |
| US-20230119060-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE | SLC5A2, SLC5A1, SLC5A6 | TUBB4A 4145/4885TUBB 4113/4885TUBA3C 3561/4885 |
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | THPO, SERPINB1, SERPINC1 | TUBB4A 1660/4885TUBB 1022/4885TUBA3C 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.